Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential

Catalysts

About ImmunityBio

ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction.

What are the underlying business or industry changes driving this perspective?

• Although ANKTIVA is already approved in BCG unresponsive nonmuscle invasive bladder cancer and authorized across 33 countries, the company still depends heavily on a single commercial asset. Any slower than expected uptake or reimbursement delays in newer regions could limit revenue growth relative to rising fixed costs.
• While the randomized QUILT 2.005 study in BCG naive bladder cancer has fully enrolled and an interim look suggested higher complete response rates with ANKTIVA plus BCG, the final blinded data and planned BLA filing in Q4 2026 still carry clinical and regulatory risk that could affect future bladder cancer revenue expansion.
• Although the conditional approval in Saudi Arabia for ANKTIVA plus checkpoint inhibitors in metastatic non small cell lung cancer opens a new use case for the IL 15 platform, the reliance on single arm data and country by country regulatory decisions means any stricter review elsewhere could temper expectations for broader lung cancer related revenue.
• While the off the shelf CAR NK, m ceNK, and DNA vaccine platforms give ImmunityBio a broad oncology toolkit, these programs are still in clinical development. Any slower trial progress, manufacturing hurdles, or combination safety issues could delay the point at which they begin to contribute meaningfully to earnings.
• Although ANKTIVA’s effect on NK and T cell counts positions the company to target conditions like lymphopenia and treatment related immune suppression, the need to run additional outcome focused trials in settings such as sepsis, radiation induced lymphopenia, and infection means any setbacks or inconclusive data could push out potential new revenue streams and keep net margins under pressure.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on ImmunityBio compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming ImmunityBio's revenue will grow by 129.4% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from -606.2% today to 42.3% in 3 years time.
• The bearish analysts expect earnings to reach $719.9 million (and earnings per share of $0.69) by about July 2029, up from -$854.5 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 26.5x on those 2029 earnings, up from -10.9x today. This future PE is greater than the current PE for the US Biotechs industry at 17.8x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.34%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• ImmunityBio remains highly dependent on ANKTIVA as its main commercial product, so any slower clinical adoption, reimbursement setbacks in newer regions, or competing therapies in bladder or lung cancer could limit the long term contribution from this backbone asset. This could put pressure on revenue growth and delay any improvement in earnings and net margins.
• The broad BioShield vision relies on successful execution across complex modalities such as off the shelf CAR NK cells, m ceNK, DNA vaccine vectors and recombinant BCG. Setbacks in clinical data, manufacturing scale up, or regulatory reviews for these programs could mean the multi platform pipeline does not translate into diversified cash flows, which would keep revenue concentrated and research and development expense heavy relative to future earnings.
• The company is pursuing approvals based in part on single arm and plausible mechanism of action pathways, especially in checkpoint inhibitor refractory lung cancer. Any shift in regulator expectations toward larger randomized data sets or a change in how accelerated approvals are granted could slow or limit label expansions, which would affect the outlook for incremental revenue and delay any path toward stronger net margins.
• International expansion into Europe, the Middle East and North Africa involves country by country reimbursement, geopolitical risk and reliance on partners such as Accord, Biopharma and Cigalah. Slower than expected market access or disruptions in these regions could cap the contribution from these territories, leading to a mismatch between commercial infrastructure spending and realized revenue and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for ImmunityBio is $12.0, which represents up to two standard deviations below the consensus price target of $13.0. This valuation is based on what can be assumed as the expectations of ImmunityBio's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $15.0, and the most bearish reporting a price target of just $12.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.7 billion, earnings will come to $719.9 million, and it would be trading on a PE ratio of 26.5x, assuming you use a discount rate of 7.3%.
• Given the current share price of $8.87, the analyst price target of $12.0 is 26.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.